Percheron Therapeutics Limited (ASX:PER)

Market Cap	7.61M -36.4%
Revenue (ttm)	1.74M -9.5%
Net Income	-9.49M
EPS	-0.01
Shares Out	1.52B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,926,031
Average Volume	2,722,504
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0050
52-Week Range	0.0040 - 0.0130
Beta	1.02
RSI	41.28
Earnings Date	May 27, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company’s lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PER

Financial Performance

In fiscal year 2025, Percheron Therapeutics's revenue was 1.80 million, a decrease of -39.32% compared to the previous year's 2.97 million. Losses were -14.92 million, 25.2% more than in 2024.